$56.61 Million in Sales Expected for Intrexon Corporation (XON) This Quarter
Equities research analysts forecast that Intrexon Corporation (NYSE:XON) will report $56.61 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Intrexon Corporation’s earnings, with estimates ranging from $50.95 million to $67.15 million. Intrexon Corporation reported sales of $46.00 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 23.1%. The business is expected to announce its next earnings results on Wednesday, March 7th.
On average, analysts expect that Intrexon Corporation will report full-year sales of $56.61 million for the current fiscal year, with estimates ranging from $202.63 million to $236.02 million. For the next year, analysts anticipate that the business will report sales of $284.29 million per share, with estimates ranging from $229.25 million to $354.20 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Intrexon Corporation.
A number of equities analysts recently commented on XON shares. Zacks Investment Research lowered shares of Intrexon Corporation from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Northland Securities reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Intrexon Corporation in a research note on Friday, October 6th. Griffin Securities reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Intrexon Corporation in a research note on Friday, October 6th. BidaskClub lowered shares of Intrexon Corporation from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 22nd. Finally, JMP Securities reissued an “outperform” rating and set a $42.00 target price on shares of Intrexon Corporation in a research note on Thursday, October 5th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Intrexon Corporation has a consensus rating of “Hold” and a consensus price target of $38.50.
Intrexon Corporation (XON) traded up $0.77 during trading on Tuesday, reaching $12.58. 7,219,600 shares of the company were exchanged, compared to its average volume of 1,110,684. Intrexon Corporation has a 1 year low of $10.25 and a 1 year high of $32.90. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.05 and a quick ratio of 1.85.
In other Intrexon Corporation news, Director Robert B. Shapiro acquired 2,850 shares of Intrexon Corporation stock in a transaction that occurred on Tuesday, August 22nd. The stock was acquired at an average price of $17.50 per share, with a total value of $49,875.00. Following the purchase, the director now owns 43,157 shares in the company, valued at $755,247.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 56.30% of the stock is currently owned by insiders.
Several hedge funds have recently added to or reduced their stakes in XON. Tower Research Capital LLC TRC raised its holdings in Intrexon Corporation by 2,031.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock worth $125,000 after acquiring an additional 4,937 shares during the period. SG Americas Securities LLC bought a new position in Intrexon Corporation in the 3rd quarter worth $139,000. Federated Investors Inc. PA bought a new position in Intrexon Corporation in the 2nd quarter worth $172,000. Quantbot Technologies LP raised its holdings in Intrexon Corporation by 423.7% in the 3rd quarter. Quantbot Technologies LP now owns 9,993 shares of the biotechnology company’s stock worth $189,000 after acquiring an additional 8,085 shares during the period. Finally, John G Ullman & Associates Inc. bought a new position in Intrexon Corporation in the 2nd quarter worth $212,000. 77.28% of the stock is owned by institutional investors and hedge funds.
Intrexon Corporation Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.